Objective To detect the expression of PEG10 in primary hepatic carcinoma (PHC)tissues,to explore its relationship between clinical pathological parameters and prognosis of PHC.Methods The expression of PEG10 was detected by immunohistochemical (SP method)in 58 carcinoma tissues of PHC patients in our hospital.The relationship between PEG10 and clinical pathological characteristics or prognosis of PHC was analyzed.Results Among 58 specimens, 44 were tested positive for PEG10,including 16 of"+",13 of"++"and 15 of"+++".The average follow-up was 40.5 months,and 23 cases (39.7%)dead by the end of follow-up .The median survival time was 31 months for all cases.And 57 months,34months,27months,15months for PEG10 "-","+","+ +","+ + +"groups,respectively.The survival rate in different groups had significant differences (P = 0.000 ).Levels of PEG10 in the female,advanced tumor, preoperative alpha fetal protein (AFP)>200ng/mL,microvascular invasion and poorly differentiated tumors cases were higher (P <0.05),while had no relation with age,tumor diameter or etiology (P >0.05).Among early recurrent cases, ratio of PEG10-positive was higher than that of PEG10-negative (P < 0.05 ),however,which showed no significant difference in late recurrent groups (P >0.05).The specificity,sensitivity and accuracy rate of PEG10 in prediction of PHC recurrence was 77.5%,38.9% and 65.5%,respectively.AJCC stage,microvascular invasion,etiology and PEG10 expression were risk factors for PHC recurrence by multivariate COX analysis (P <0.05 ),in which PEG10 positive HR was 6.724.Conclusion PEG10 can effectively predict the prognosis of PHC with a high specificity but low sensitivity, which should be conjunct with other indicators to make a comprehensive evaluation.%目的：检测 PEG10在原发性肝癌（PHC）组织中表达的情况，探讨其与临床病理参数的关系及对肝癌预后的临床意义。方法应用免疫组织化学方法（SP 法）检测58例 PHC 患者肝组织中 PEG10的表达情况，并分析 PEG10与PHC 临床病理特征及预后的关系。结果58份 PHC 标本中44份 PEG10阳性，其中“＋”16份、“＋＋”13份和“＋＋＋”15份。平均随访时间为40．5 m，至随访结束时共有23例（39．7％）患者死亡；所有患者中位生存时间为31 m，PEG10表达为“－”、“＋”、“＋＋”、“＋＋＋”的中位生存时间分别为57、34、27和15 m，不同 PEG10表达组间生存率差异有统计学意义（P ＝0．000）；PEG10在女性、晚期病例、术前 AFP＞200 ng ／mL、微血管侵犯、低分化肝癌患者肿瘤组织中表达更高（P ＜0．05），而与患者年龄、肿瘤直径、病因无关（P ＞0．05）；早期复发病例中 PEG10阳性比例明显高于阴性（P ＜0．05），而晚期复发病例组间无明显差异（P ＞0．05）。PEG10预测 PHC 复发的诊断特异度77．5％，敏感度为38．9％，准确率为65．5％，多因素 COX 模型中 AJCC 分期、微血管侵犯、病因和 PEG10表达是影响 PHC 预后的危险因素（P ＜0．05），其中 PEG10阳性的 HR 达6．724。结论 PEG10对 PHC 预后具有很好的评估价值，但是其特异性高而敏感性不高，需要联合其他指标作出综合评价。
展开▼
